Table 4.
Diagnostic performance for MVI of cHCC-CCA
| AUC (95% CI) | Sensitivity | Specificity | Accuracy | PPV | NPV | |
|---|---|---|---|---|---|---|
| AAPR | 0.560 (0.456, 0.663) | 15.2 (9/59) | 96.7 (58/60) | 56.3 (67/119) | 81.8 (9/11) | 53.7 (58/108) |
| ANRI | 0.585 (0.483, 0.688) | 25.4 (15/59) | 91.7 (55/60) | 58.9 (70/119) | 75.0 (15/20) | 55.6 (55/99) |
| Non-smooth margin | 0.614 (0.512–0.715) | 66.1 (39/59) | 60.0 (34/60) | 61.3 (73/119) | 60.0 (39/65) | 63.0 (34/54) |
| Arterial phase peritumoral enhancement | 0.740 (0.648, 0.831) | 78.0 (46/59) | 70.0 (42/60) | 73.9 (88/119) | 71.9 (46/64) | 76.4 (42/55) |
| Imaging model | 0.759 (0.671, 0.847) | 78.0 (46/59) | 70.0 (42/60) | 73.9 (88/119) | 71.9 (46/64) | 76.4 (42/55) |
| Combined model | 0.802 (0.724, 0.881) | 83.1 (49/59) | 66.7 (40/60) | 74.8 (89/119) | 71.0 (49/69) | 80.0 (40/50) |
Imaging model model only using imaging data, Combined model combined inflammatory biomarkers with imaging features, AUC area under the curve, PPV positive predictive value, NPV negative predictive value